CHROMONAR HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H27NO5.ClH
Molecular Weight	397.893
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CCOC(=O)COC1=CC2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2

InChI

InChIKey=KSQIAZKOUOEHSA-UHFFFAOYSA-N

InChI=1S/C20H27NO5.ClH/c1-5-21(6-2)11-10-17-14(4)16-9-8-15(12-18(16)26-20(17)23)25-13-19(22)24-7-3;/h8-9,12H,5-7,10-11,13H2,1-4H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C20H27NO5
Molecular Weight	361.4321
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://lekarstwo.ru/en/preparati/carbocromenum.html
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800000219

Chromonar is a coronary vasodilator agent, it dilates coronary vessels and increases coronary blood flow volume rate, contributes to the development of collateral circulation (with prolonged use), improves metabolic processes in myocardium. The mechanism of action of a role played by its inhibitory effect on phosphodiesterase, accompanied by accumulation in the cells of cyclic 3 ', 5'-adenosine monophosphate. Due to the relatively low therapeutic efficacy Chromonar use is limited, mainly in the early stages of coronary heart disease with angina pectoris in the absence of long-standing and long strokes, when there is no expressed stenotic process.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Platelet Aggregation (Plug Formation) 5 Target ID: WP1884 Sources: http://www.ncbi.nlm.nih.gov/pubmed/947200	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Coronary artery disease 48 Sources: http://www.ncbi.nlm.nih.gov/pubmed/756818	Primary		Approved 8429	Intensain Approved Use Indications for use: Angina without expressed stenotic process protracted and prolonged attacks, postinfarction period.

PubMed

Title	Date	PubMed
Cardioprotective effects of carbocromen in awake and anesthetized dogs with amitriptyline poisoning.	1985 Jul-Aug	2410706
Protective actions of carbocromene against amitriptyline-induced cardiotoxicity in anesthetized rats.	1986 Jan	3963932
Cloricromene, a semi-synthetic coumarin derivative, inhibits tumor necrosis factor-alpha production at a pre-transcriptional level.	2001 Apr 27	11343695
Intradermal injection vs. oral treatment of tinnitus.	2001 Jul-Aug	11677863
Effect of estrogen replacement therapy on distribution of myocardial blood flow in female anesthetized rabbits.	2001 Sep	11514313
Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography.	2002 Feb 5	11863286
Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats.	2003 Mar	12601047
Preparation and characterization of solid lipid nanoparticles containing cloricromene.	2003 Oct-Dec	14612340
A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat.	2004 Apr 16	15043989
Cloricromene in endotoxemia: role of NF-kappaB.	2004 Aug	15322736
Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene.	2004 Jul	15233861
In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form.	2004 Jun 18	15158956
Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats.	2006 Apr	16572308
Cloricromene effect on the enzyme activities of the tryptophan-nicotinic acid pathway in diabetic/hyperlipidemic rabbits.	2006 Jan 18	16126232
Enhancement of availability of cloricromene at brain level by a lipophilic prodrug.	2006 Jul	16805962
Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.	2006 Mar 24	16584158
Retinal and systemic pharmacokinetics of the anti-inflammatory drug cloricromene following oral administration in the rat and rabbit.	2007 Jun	17593009
Protective effects of a coumarin derivative in diabetic rats.	2009 Aug	19279317
Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins.	2010 Jan 12	20110890

Patents

Sample Use Guides

In Vivo Use Guide

Inside after food: 0,075 - 0,15 g (1 - 2 tablets) 3 times a day. In more severe cases, to begin receiving 0.15 g 4 times a day, and after improving the dose is reduced to 0.075 g of 3 - 4 times daily. It is noted that the effect of the drug increases (to 10 - 30th day) and lasts a long time. Take in a few weeks or months (up to 6 months).

Route of Administration: Oral

In Vitro Use Guide

In bovine heart mitochondria ho/h-1 ratios in repeated scans increased in presence of carbocromen (20--40 umol/l)

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:13:46 GMT 2023` Edited by `admin` on `Fri Dec 15 15:13:46 GMT 2023`
Record UNII	52C937V399
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHROMONAR HYDROCHLORIDE

Official Name

English

NSC-110430

Code

English

CHROMONAR HYDROCHLORIDE [USAN]

Common Name

English

[[3-[2-(Diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]acetic acid ethyl ester hydrochloride

Systematic Name

English

CARBOCROMEN HYDROCHLORIDE [JAN]

Common Name

English

A-27053

Code

English

CARBOCROMEN HYDROCHLORIDE

Common Name

English

Carbocromen hydrochloride [WHO-DD]

Common Name

English

CHROMONAR HCL

Common Name

English

AG-3

Code

English

ACETIC ACID, ((3-(2-(DIETHYLAMINO)ETHYL)-4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-YL)OXY)-, ETHYL ESTER, HYDROCHLORIDE

Common Name

English

CARBOCROMEN HYDROCHLORIDE [MART.]

Common Name

English

CHROMONAR HYDROCHLORIDE [MI]

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C166807